GLP-1 Drugs Linked to Lower Cancer Risk than Insulin
A study of 359,595 adults found lower rates of obesity-related cancers over three years compared to insulin and sulfonylureas.
Lower Three-Year Cancer Risk Compared to Insulin
Adults starting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) had a lower risk of developing obesity-related cancers over three years than those who started insulin or sulfonylureas. The study, published in JAMA Network Open, evaluated electronic health records from patients with type 2 diabetes.
The difference in estimated cancer risk was 1.25 percentage points compared with insulin. The difference was 1.14 percentage points compared with sulfonylureas over the three-year tracking window.
How Researchers Structured the Health Record Analysis
Researchers analyzed records from 359,595 adults treated at University of Texas Southwestern Medical Center (UT Southwestern Medical Center) between January 1, 2010, and July 31, 2025. The study used a framework called target trial emulation to replicate the design features of a clinical trial using real-world medical data.
Eligible participants had type 2 diabetes with no prior history of obesity-related cancer. The protocol required a washout period of at least 365 days without the evaluated medication before treatment start, ensuring the data reflected new drug initiations rather than ongoing therapy.
- Metformin
- Insulin
- Sulfonylureas
- Sodium-glucose cotransporter-2 (SGLT2) inhibitors
- Dipeptidyl peptidase-4 (DPP-4) inhibitors
Accounting for Diabetes Severity and Complications
Prescribing decisions often align with how long a person has had diabetes and whether organ damage exists. Patients with advanced kidney or blood vessel disease frequently receive insulin later in their disease progression, which can alter baseline cancer risk.
To address this confounding factor, the team split participants into three tiers based on diabetes severity from low to high. Patients were followed until their first obesity-related cancer diagnosis, death, final clinic visit, or completion of three to five years of follow-up.
Limitations and Comparison with Other Diabetes Drugs
The lower risk estimate appeared specifically against insulin and sulfonylureas, not across every alternative medication. The study did not find this same risk difference when comparing GLP-1 RAs to metformin, SGLT2 inhibitors, or DPP-4 inhibitors.
This research was an observational analysis based on records from a single academic medical center. While the target trial design controlled for recorded severity, observational data cannot establish direct cause and effect. Patients evaluating diabetes medications should review their specific risk factors with their healthcare provider.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.


Related Articles
Type 1 Diabetes Score Misses Remissions in Youth with Obesity
A Diabetes Care study finds insulin dose-adjusted hemoglobin A1c (IDAA1c) misses over half of...
Read article MetabolismStudy Finds Widening Disparities in Weight-Loss GLP-1 Access
A study of 512,389 commercially insured adults found that access gaps for weight-loss GLP-1...
Read article MetabolismGlucose-Powered Implant Improves Blood Sugar in Animal Study
A study in Nature reports on NeuroAxis, an experimental implant powered by glucose that...
Read article MetabolismNatural Peptide Protects Retinal Cells in Laboratory Diabetes Model
A study in Biomedicine & Pharmacotherapy shows the Annexin A1 peptide Ac2-26 shields retinal...
Read articleWant medical weight loss instead of another diet?
Opt Health prescribes and monitors GLP-1 therapy against real labs — insulin, A1C, lipids, thyroid, hormones — so the plan fits your physiology rather than a generic protocol. Medication ships to your door.
See Opt Health's weight-loss program →Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Understand Your Health Better
Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.